Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers

Pharmaceutical Research

Volumn 16, Issue 5, 1999, Pages 625-632

  Raeissi, Shamsi D ^a   Hidalgo, Ismael J ^a   Segura Aguilar, Juan ^b   Artursson, Per ^b  

^a Drug Safety and Metabolism   (United States)

^b NONE

Author keywords

Caco 2; CYP3A; Cytochrome P450; Intestinal metabolism; TC7; Terfenadine

Indexed keywords

CYTOCHROME P450; TERFENADINE;

ARTICLE; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME BINDING; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; PRIORITY JOURNAL;

ANTI-ANXIETY AGENTS; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CATALYTIC DOMAIN; CELL POLARITY; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIGOXIN; ENZYME INHIBITORS; EPITHELIAL CELLS; GENE EXPRESSION; HISTAMINE H1 ANTAGONISTS; HUMANS; HYDROXYLATION; INTESTINES; KETOCONAZOLE; KINETICS; OLIGONUCLEOTIDE PROBES; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PIPERIDINES; RNA, MESSENGER; TERFENADINE; TRITIUM; VERAPAMIL;

EID: 0032940697     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018851919674     Document Type: Article

References (30)

1. 1. L. S Kaminsky, and M. J. Fasco. Small intestinal cytochrome P450. Toxicology 21:407-422 (1992).
2. 2. A. P. Li, D. L. Kaminski, and A. Rasmussen. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8 (1995).
3. 3. W. Chi-Yuan, L. Z. Benet, M. F. Hebert, S. K. Gupta, M. Rowland, D. Y. Gomez, and V. J. Wacher. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporin. Clin. Pharmacol. Ther. 58:492-497 (1995).
4. 4. K. E. Thummel, D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and G. R. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491-502 (1996).
5. 5. V. J. Wacher, C.-Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implication for drug delivery and activity in cancer chemotherapy. Carcinogenesis 13:129-134 (1995).
6. 6. A. H. Schinkel, U. Mayer, E. Wagenaar, C. A. Mol, L. van Deemeter, J. J. Smit, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, J. M. Zijlmans, W. E. Fibbe, and P. Borst. Normal viability and altered pharmaceutics in mice lacking mdr1 - type (drug-transporting) P-glycoproteins. Med. Sci. 94:4028-4033 (1997).
7. 7. A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Pharmacology 94:2031-2035 (1997).
8. 8. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
9. 9. K. S. Lown, R. R. Mayo, A. B. Leichtman, H-L. Hsiao, K. Turgeon, P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, and P. B. Watkins. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:248-260 (1997).
10. 10. R. Sandstrom, A. Karlsson, L. Knutson, and H. Lennernäs. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res. 15:856-862 (1998).
11. 11. X. Boulene, M. Bourrie, I. Fabre, C. Roque, H. Joyeux, Y. Berger, and G. J. Fabre. Regulation of cytochrome P450IA1 expression in a human intestinal cell line, Caco-2. J. Pharmacol Exp. Ther. 263:1471-1478 (1992).
12. 3. Mol. Pharmacol. 51:741-754 (1997).
13. 13. V. Carriere, T. Lesuffleur, A. Barbat, M. Rousset, E. Dussaulx, P. Costet, I. de Waziers, P. Beaune, and A. Zweibaum. Expression of cytochrome P450 3A in HT29-MTX cells and Caco-2 Clone TC7. FEBS Lett. 355:247-250 (1994).
14. 14. L. Gervot, V. Carriere, P. Costet, P-H. Cugnene, A. Berger, P. H. Beaune, and I. de Waziers, CYP3A5 is major cytochrome P450 3A expressed in human colon and colonic cell lines. Environ. Toxicol Pharmacol. 2:381-388 (1996).
15. 15. S. D. Raeissi, Z. Guo G. L. Dobson P. Artursson, and I. J. Hidalgo. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine. Pharm. Res. 14:1019-1025 (1997).
16. 16. D. A. Garteiz, R. H. Hook, B. J. Walker, and R. A. Okerholm. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung 32:1185-1190 (1982).
17. 17. K. T. Kirvisto, P. J. Neuronen, and U. Klotz. Inhibition of terfenadine metabolism: Pharmacokinetics and pharmacodynamic consequences. Clin. Pharmacokinet. 27:1-5 (1994).
18. 18. I. de Waziers, P. H. Cugnene, C. S. Yang, J.-P. Leroux and P. H. Beaune. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387-394 (1990).
19. 19. M. G. Mercurio, S. J. Shiff, R. A. Galbraith, and S. Sassa. Expression of cytochrome P450 mRNAs in the colon and the rectum in normal human subjects. Biochem. Biophys. Res. Commun. 210:350-355 (1995).
20. 20. J. Kolars, K. S. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. A. Wrighton, R. M. Merion, and P. B. Watkins. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259 (1994).
21. 21. 24. M. H. Gault, L. L. Longerich J. C. K. Lou, P. T. H. Ko, A. Fine, S. C. Vasdev, and M. A. Dawe. Digoxin biotransformation. Clin. Pharmacol. Ther. 35:74-82. (1984).
22. 22. B. Lacarelle, R. Rahmani, G. de Sousa, A. Durand, M. Placidi, and J. P. Cano. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam. Clin. Pharmacol. 5:567-582 (1991).
23. 23. H. Engman, H. Lennern̈s, and P. Artursson. Expression of cytochrome P450 3A4 and MDR1 in normal and transformed human intestinal epithelial cell lines. Pharm. Res. (supplement) 15:S6 (1998).
24. 24. A. Zweibaum, H. P. Hauri, E. Sterchi, I. Chantret, K. Haffen, J. Bamat, and B. Sordat. Immunohistological evidence obtained with monoclonal antibodies, of small intestinal brush border hydrolases in human colon cancers and foetal colons. Int. J. Cancer 35:591-598 (1984).
25. 25. W. N. Hait, J. F. Gesmonde, J. R. Murren, J. Yang, H. Chen, and M. Reiss. A new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem. Pharmacol. 45:401-406 (1995).
26. 26. A. Seelig. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 251:252-261 (1998).
27. 27. J. Karlsson, S-M. Kuo, J. Ziemniak, and P. Artursson. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1009-1016 (1993).
28. 28. R. Sandstrom. Intestinal permeability and presystemic metabolism of R/S-verapamil and fluvastatin. Thesis 185, Uppsala University Library (1998).
29. 29. K. S. Lown, R. R. Mayo, A. B. Leichtman, H. L. Hsiao, D. K. Turgeon, R. P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, and P. B. Watkins. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailabilily of cyclosporine. Clin. Pharmacol. Ther. 62:248-260 (1997).
30. 30. T. J. Raub, C. L. Barsuhn, L. R. Williams, D. E. Decker, G. A. Swada, and N. F. Ho. Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J. Drug Target. 1:269-286 (1993).